Effectiveness, safety, neurologic outcome, and hemorrhage expansion in groups treated with intensive versus standard blood pressure decreasing.* 
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METHODS

DATA SOURCES
The authors performed a search of PubMed, EMBASE, and the Cochrane databases, with the last search conducted June 10, 2016. They also reviewed bibliographies for additional records and checked the references of the publications until no further publications were found.
STUDY SELECTION
Randomized controlled trials reporting functional outcomes of acute blood pressure decreasing in patients with intracerebral hemorrhage were included for analysis. Primary outcomes were 3-month mortality and significant disability (using a modified Rankin Scale score >3). Secondary outcomes were rates of substantial hemorrhage expansion and serious adverse events.
DATA EXTRACTION AND SYNTHESIS
Three authors independently extracted data with a standardized form and assessed study quality. A random-effects model was used in all analyses. Results were reported as odds ratios with 95% confidence intervals. Trial quality was assessed with the Cochrane Collaboration tool. Heterogeneity was assessed with the I 2 statistic and qualitatively with forest plot inspection. Publication bias was assessed with a funnel plot. This meta-analysis assessed the clinical benefit of intensive blood pressure control (goal systolic blood pressure <140 mm Hg) compared with standard blood pressure control (goal systolic blood pressure <180 mm Hg) during the acute phase of intracerebral hemorrhage. The authors concluded that intensive blood pressure decreasing did not significantly decrease the risk of mortality or lead to improved functional outcomes at 90 days compared with standard blood pressure decreasing. Another recent meta-analysis also found a decreased rate of hematoma expansion at 24 hours, but no difference in mortality or disability at 90 days. 4 The authors of that study similarly concluded that although aggressive blood pressure control was safe, it did not provide clinical benefit in comparison with standard blood pressure control at 90 days. 
